Summary.-We measured the effect of 6 standard (Adriamycin, BCNU, DTIC, melphalan, vinblastine, actinomycin D) These investigations furnish a quantitative description of the chemosensitivity of human metastatic melanoma CFU. Additionally, these studies serve as a useful step towards the development of an in vitro chemosensitivity test for human melanoma, and provide an operational quantitative basis for further exploration of in vitrodirected therapy in metastatic neoplasms.
The treatment of metastatic melanoma is currently unsatisfactory. The number of anticancer drugs known to be active is small, and they produce low response rates with few complete remissions (Einhorn et al., 1974 ). An assay to identify useful chemotherapeutic agents in melanoma would represent a major advance.
Hamburger & Salmon (1977) have developed a simple bi-layer agar system which allows the growth of human tumour stem cells from a variety of tumours (Salmon, 1980) , including melanoma . Tumour stem cells are defined as those with self-renewal properties which are responsible for repopulation of a tumour in vivo. In vitro these cells can most readily be identified by their clonogenic or colony-forming ability. One method which functionally identifies clonogenic cells is the tumour stem-cell assay, which has shown considerably accurate prediction of clinical sensitivity and resistance in a variety of human tumours (Salmon et al., 1978; 1980b; Von Hoff et al., 1981) and detailed studies have been carried out on the use of this assay in multiple myeloma (Durie et al., 1981) ovarian cancer (Alberts et al., , 1981b and other neoplasms. We have also presented data on ovarian cancer and malignant melanoma which suggests that the assay may be used as an in vitro Phase II clinical trial .
In this report we (Salmon, 1980 N-(4-(9-acridinylamino)-3 methoxyphenyl) (AMSA) were prepared in sterile buffered saline or water and stored at -70°C in aliquots sufficient for individual assays. Subsequent dilutions were made in saline for cell incubation. Tumourcell suspensions were transferred to tubes and adjusted to a final concentration of 106/ml in the appropriate drug or control medium. Each drug was tested at concentrations that we calculated from pharmacokinetic data as pharmacologically achievable in vivo. Final concentration ranges (in ,ug/ml) were 0-01-0-30 for ADR, 0 05-3 0 for BCNU, 0-05-1.0 for DDP and DTIC, 0 05-0 40 for PAM, 0-01-1-0 for VLB and AMSA, and 0.0001-0.1 for Act D and VDE.
Single-cell suspensions were prepared from tumour biopsy by mechanical techniques described previously (Hamburger & Salmon, 1977; Salmon et al., 1978) . Cells were incubated with or without drugs for 1 h at 37°C in Hanks' balanced salt solution. The cells were then centrifuged at 150 g for 10 min, washed twice with serum-free medium and prepared for culture. Loss of cells during this procedure was <5% in both the control and drug-treated samples. Culture assay for tumour colony-forming cells-.The culture system has been extensively described (Salmon et al., 1978; Salmon, 1980; Meyskens et al., 1981 (Salmon & Buick, 1979) and a combination of Papanicolaou and melanin staining (Mishima, 1960) . Melanoma colonies from these patients expressed melanin pigmentation, which served as a marker of neoplastic origin of the colony-forming cells Previous experience with the assay has suggested that survival of TCFU at onetenth the calculated pharmacologically achievable concentration x lh ("cut-off" concentration) provides a useful parameter to relate to clinical response (see Moon et al., 1980 Moon et al., , 1981 . The "cut-off" concentrations specified were 0 01,ug/ml for 1 h for Act D, VDE, and VLB and 0410 ,ug/ml for lh for the remaining drugs. These concentrations were selected on the basis of an extensive compilation of the literature and our own pharmacokinetic studies. The doses necessarily represent an approximation to drug concentrations that would be found in an individual patient. On the basis of training sets of in vitro/in vivo correlations in experiments with ovarian cancer (Alberts et al., 1980b) and multiple myeloma (Durie et al., 54 1981 ) and on the current study, patients with melanoma were classified as sensitive if survival of TCFU was < 38% at the "cut-off" concentration and resistant if >38%. This simple approach to classifying in vitro response has developed from a careful analysis of the more complex "area under the curve" (Moon et al., 1980 (Moon et al., , 1981 and should be viewed as an operational method of determining in vitro chemosensitivity and relating TCFU survival to clinical response.
RESULTS

Survival of melanoma TCFU at "cut-off" concentration
We have examined the effect of a series of drugs on melanoma TCFU. The percentage survivals of melanoma TCFU at the "cut-off" concentration of Act D are profiled in the Figure and summarized in Table I for the 9 drugs tested. The Figure graphically demonstrates the marked heterogeneity of response to a drug of melanoma TCFU, both within a tumour and between tumours, and the frequent presence of a plateau of drugresistant TCFU even at very high drug concentrations. Using the operational definition of 38% TCFU survival at the "cut-off" concentrations to define in vitro sensitivity (Table I) , the percentage of tumour stem cells sensitive to the different drugs were: PAM, 36%; ADR, 30%; DDP, 27%; Act D, 26%; AMSA, 20%; VDE, 14%; BCNU, 12%; DTIC, 9%; VLB, 8%.
The effects on inelanoma TCFU of two drugs with similar actions were compared. In 4 patients (Nos 22-25) the effect of ADR and AMSA on TCFU was simultaneously available. The TCFU survival at 0-10 ,ug/ml for ADR vs AMSA were (in %) 23 vs 19, 30 vs 56, 96 vs 18, and 111 vs 79. The effect of VLB and VDE on TCFU was also simultaneously assessed in 8 patients (No. 33, 38, 30, 42, 45, 47, 48, 49 studies and the number of drugs in each investigation in relationship to the number and percentage of instances in which TCFU survival was reduced to < 38% at the "cut-off" concentration. The results show that with more drugs tested there was a significant increase in the proportion of studies in which at least one effective drug was found (P < 0 000 1). For a high probability of detecting at least one active drug, at least 6 drugs should be tested in any assay.
In vitro/in vivo correlations with Act D
We have sufficient in vitro and in vivo clinical data with Act D to begin to assess the relation of in vitro sensitivity to this agent to clinical response. The correlation of in vitro/in vivo correlations for Act D is shown in Table IV , and includes mixed responses as responses. The in vivo response rate was 0 353 (S/S)/(S/S+R/S).
Above 35% TCFU survival the predicted in vivo response was > 0-83, and fell at lower TCFU survival (which suggested a break-point) particularly since the true positive (S/S)/(S/S + S/R) in vivo/in vitro correlation continued to increase with decreasing TCFU survival. In contrast, the true negative (R/R)/(R/R + R/S) in vitro/in vivo correlation was maximal (0.90) at 35% TCFU survival. The extended calculations indicate that 38% TCFU survival gives the best fit of predicted in vivo repsnse and true negative in vitro/in vivo correlation. These results demonstrate the method by which an acceptable level of correlation for sensitivity (S/S)/(S/S + S/R) or resistance (R/R)/ (R/R + R/S) can be determined using percentage survival at the "cut-off" concentration. For example, at 50% TCFU survival predictive accuracy for sensitivity was 56% (5/9) and for resistance 88% (7/8). In contrast, at a 20% TCFU survival the predictive accuracy for sensitivity was 100% (2/2) and for resistance 73% (11/15).
Overall experience with clinical correlation
The in vitro melanoma TCFU and in vivo clinical response were compared in the 50 melanoma patients treated with a variety of anticancer drugs (Tables V, VI) . The 38% in vitro "cut off" concentration was derived using the 48 correlations in 41 patients with melanoma. The approach was the same as that detailed above for Act D (Table IV) Table VI . In 6 cases the patient had no prior therapy, but in the other 6 the patients had previously received 1-6 drugs (mean= 3). In 4 clinical trials only single agents were used, and in 8 trials more than one agent was used.
DISCUSSION
It is clear from these studies that human melanoma TCFU exhibit marked heterogeneity in chemosensitivity to the 6 standard agents (ADR, BCNU, DTIC, PAM, VLB, and Act D) and 3 Phase II agents (DDP, VDE, AMSA) tested. Reduction in survival of TCFU to less than 38% at one-tenth the pharmacologically achievable concentration occurred in only 19% of 200 in vitro trials with these 9 drugs in the 50 patients studied. These results are, in general, similar to those obtained in our centre for chemosensitivity testing of ovarian cancer and multiple myeloma (Durie et al., 1981) . However, in contrast to melanoma TCFU, ovarian and myeloma tumour stem cells which had not been exposed to prior chemotherapy in vivo were much more sensitive to chemotherapy in vitro (Durie et al., 1981; . For example, found significantly more chemosensitivity in untreated patients than in previously treated patients with ovarian cancer for DDP, ADR and bleomycin.
The fact that melanoma cells from untreated patients were no more sensitive to the drugs tested than cells from previously treated patients (Table II) suggest that most melanoma TCFU are inherently resistant to presently available chemotherapeutic agents. Until more effective agents are identified, the acquisition of drug resistance or cross resistance between agents cannot be easiy approached in human melanoma, unless serial biopsies were studied from individual patients. The apparent increased sensitivity of melanoma TCFU from patients previously treated with ADR remains unexplained, and merits further laboratory and clinical investigation.
An important goal in the development of an in vitro predictive assay is determination of the minimum number of drugs to be tested in vitro to identify at least one agent with a high probability of being effective in vivo. Our data indicate that the frequency of identifying potentially effective drugs increases with the number of drugs tested per melanoma specimen (Table III) . If > 6 drugs were tested, a drug producing <,38% survival at the "cut-off" concentration was found in all cases (10/10). On the basis of our in vitro/in vivo correlations for melanoma (Tables VI, VII) we can predict that patients who are sensitive in vitro will (Einhorn et al., 1974) and to the best combination chemotherapy is 30-melanoma. The conceptual and practical steps involved in determining in vitro TCFU 794 DRUG SENSITIVITY OF MELANOMIA CFU sensitivity and obtaining clinical correlations has been extensively reviewed elsewhere (Salmon, 1980; Moon et al., 1980; . Initially, a training set of in vitro drug-survival curves and clinical-response data was analysed, and clinical sensitivity and resistance were related to an area under the survival curve with increasing drug concentrations in vitro (Moon et al., 1980; . Pharmacological considerations provided further understanding of this system. Reduced survival of TCFU at low drug concentrations (< 10% of the pharmacologically achievable I h concentration for drugs with a short half-life) in vitro proved important for identifying ranges of drug concentrations relevant for predicting clinical response. This system has been further refined and operationally simplified, such that if the pharmacology of a drug is reasonably well known, in vitro/in vivo correlations can be simply related to percentage survival of TCFU at the "cut-off" concentration. The use of this latter approach is seen in Table IV for Act D and metastatic melanoma. The acquisition of further data for specific tumours and drugs will allow further refinement. With presently available information, < 38% colony survival has served as a useful demarcation between clinical sensitivity and resistance. It is important to emphasize that with further in vitro/in vivo experience this discrimination point may change.
Except for the higher frequency of mixed responses in melanoma, the correlation of in vitro TCFU survival and clinical response for metastatic melanoma is very similar to our results for ovarian cancer multiple myeloma (Durie et al., 1981) , and a variety of other tumours , an observation which has been confirmed by other groups (Von Hoff et al., 1981; Mann etal., 1981) .
Important corroborations of our findings have recently been reported in studies of human melanoma xenografts studied both in vivo in immunodeficient mice and in vitro in agar culture (Courtenay & Mills, 1978; Fodstad et al., 1980; Bateman et al., 1980; Tveit et al., 1980; Selby & Steel, 1981) . However, important differences between our results and these investigators exist. Our PE is usually in the range 0-01-0-1%, whilst the PE in xenografts and agar diffusion chambers has been closer to 1-5%. We have also frequently seen plateaus in colony survival with increasing drug concentrations, while a linear decrease in colony survival has been recorded in the other systems. There are innumerable possible explanations for these differences. The most important consideration is to determine the nature of the "resistant" colonies in the plateau. This plateau may be real and may represent a subfraction of resistant clonogenic cells which are not grown in the other systems. Alternatively, the plateau may represent clonogenic cells which have received sublethal damage and are destined to die if allowed to replicate further. The plateau "survivors" do not represent aggregates, as they are not present within 24 h of plating, but developed and grew in the agar and are not morphologically distinguishable from melanoma colonies on control plates. To directly assess the reason for the plateau will require replating of dispersed cells from the resistant colonies in the absence and presence of the drug.
In our studies, sensitivity or resistance to agents such as DTIC in vitro corresponded with efficacy of the drug in vivo as well. Both our studies and those of Tveit et al. (1980) with human melanoma xenografts, indicate that DTIC activity in vitro is an indicator of clinical response. Previously, there had been one report suggesting that in vivo bioactivation was required for DTIC (Loo et al., 1976) ; this now appears less likely.
Overall, our investigations provide a quantitative description of drug sensitivity of human metastatic melanoma TCFU to a series of agents, with somewhat more success than we anticipated for a tumour that is generally considered drug resistant. Additionally, as has also been 795 the case with other neoplasms, the assay is quite accurate (86%) in melanoma for identifying drugs to which the tumour will be resistant. From the clinical standpoint, prospective identification of drug resistance can spare patients needless expense and toxicity from useless agents. The data also suggest: (a) that meaningful clinical responses are more likely to be associated with a TCFU survival below 38% at low drug concentrations, and (b) minimally active drugs may be identified by accepting higher levels of survival of TCFU. These studies also demonstrate that drug resistance in human melanoma TCFU is often present before any drug exposure in vivo. These observations imply that melanoma TCFU are frequently resistant to presently available drugs, and that either new classes or new modalities of therapy will be needed to treat melanoma.
